CN112592976A - 一种检测met基因扩增的方法及装置 - Google Patents
一种检测met基因扩增的方法及装置 Download PDFInfo
- Publication number
- CN112592976A CN112592976A CN202011604267.3A CN202011604267A CN112592976A CN 112592976 A CN112592976 A CN 112592976A CN 202011604267 A CN202011604267 A CN 202011604267A CN 112592976 A CN112592976 A CN 112592976A
- Authority
- CN
- China
- Prior art keywords
- sample
- copy number
- chromosome
- met gene
- quality control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101150105382 MET gene Proteins 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims abstract description 43
- 230000004544 DNA amplification Effects 0.000 title abstract description 22
- 239000000523 sample Substances 0.000 claims abstract description 135
- 210000000349 chromosome Anatomy 0.000 claims abstract description 103
- 239000013068 control sample Substances 0.000 claims abstract description 58
- 238000012163 sequencing technique Methods 0.000 claims abstract description 53
- 230000003321 amplification Effects 0.000 claims abstract description 45
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 45
- 238000004458 analytical method Methods 0.000 claims abstract description 33
- 238000003908 quality control method Methods 0.000 claims description 62
- 230000035772 mutation Effects 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 38
- 239000002773 nucleotide Substances 0.000 claims description 30
- 125000003729 nucleotide group Chemical group 0.000 claims description 30
- 210000001519 tissue Anatomy 0.000 claims description 30
- 210000004602 germ cell Anatomy 0.000 claims description 24
- 238000012165 high-throughput sequencing Methods 0.000 claims description 21
- 230000036438 mutation frequency Effects 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 238000002864 sequence alignment Methods 0.000 claims description 4
- 238000007482 whole exome sequencing Methods 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 238000004364 calculation method Methods 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 238000012070 whole genome sequencing analysis Methods 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 239000002547 new drug Substances 0.000 abstract description 3
- 238000007877 drug screening Methods 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 4
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000002230 centromere Anatomy 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000036086 Chromosome Duplication Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 2
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000009203 Sema domains Human genes 0.000 description 2
- 108050000099 Sema domains Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000012850 discrimination method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 101500016898 Arabidopsis thaliana C-terminally encoded peptide 7 Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000009161 IPT domains Human genes 0.000 description 1
- 108050000019 IPT domains Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940121646 third-generation egfr tyrosine kinase inhibitor Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
MET基因拷贝数 | 7号染色体拷贝数 | 胚系杂合突变差值的绝对值 | 判断结果 |
5.37 | 3.47 | 11.25% | 7号染色体扩增 |
MET基因拷贝数 | 7号染色体拷贝数 | 胚系杂合突变差值的绝对值 | 判断结果 |
22.24 | 2.24 | 5.4% | MET基因扩增 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604267.3A CN112592976B (zh) | 2020-12-30 | 2020-12-30 | 一种检测met基因扩增的方法及装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011604267.3A CN112592976B (zh) | 2020-12-30 | 2020-12-30 | 一种检测met基因扩增的方法及装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112592976A true CN112592976A (zh) | 2021-04-02 |
CN112592976B CN112592976B (zh) | 2021-09-21 |
Family
ID=75203947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011604267.3A Active CN112592976B (zh) | 2020-12-30 | 2020-12-30 | 一种检测met基因扩增的方法及装置 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112592976B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114512183A (zh) * | 2022-01-27 | 2022-05-17 | 北京吉因加医学检验实验室有限公司 | 一种预测met基因扩增或多倍体的方法及装置 |
CN115376609A (zh) * | 2022-10-24 | 2022-11-22 | 广州燃石医学检验所有限公司 | 一种判别met基因拷贝数扩增类型的方法及装置 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106062214A (zh) * | 2013-12-28 | 2016-10-26 | 夸登特健康公司 | 用于检测遗传变异的方法和系统 |
WO2016183106A1 (en) * | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
CN107423534A (zh) * | 2016-05-24 | 2017-12-01 | 郝柯 | 基因组拷贝数变异的检测方法和系统 |
CN107526941A (zh) * | 2017-09-22 | 2017-12-29 | 至本医疗科技(上海)有限公司 | 拷贝数变异检测预处理装置、检测装置、判定装置和系统 |
CN109971852A (zh) * | 2014-04-21 | 2019-07-05 | 纳特拉公司 | 检测染色体片段中的突变和倍性 |
CN111718982A (zh) * | 2020-07-09 | 2020-09-29 | 深圳市海普洛斯生物科技有限公司 | 一种肿瘤组织单样本体细胞突变检测方法及装置 |
WO2020244654A1 (en) * | 2019-06-06 | 2020-12-10 | Apollomics Inc. (Hangzhou) | Method for treating cancer patients using c-met inhibitor |
-
2020
- 2020-12-30 CN CN202011604267.3A patent/CN112592976B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106062214A (zh) * | 2013-12-28 | 2016-10-26 | 夸登特健康公司 | 用于检测遗传变异的方法和系统 |
CN109971852A (zh) * | 2014-04-21 | 2019-07-05 | 纳特拉公司 | 检测染色体片段中的突变和倍性 |
WO2016183106A1 (en) * | 2015-05-11 | 2016-11-17 | Natera, Inc. | Methods and compositions for determining ploidy |
CN107423534A (zh) * | 2016-05-24 | 2017-12-01 | 郝柯 | 基因组拷贝数变异的检测方法和系统 |
CN107526941A (zh) * | 2017-09-22 | 2017-12-29 | 至本医疗科技(上海)有限公司 | 拷贝数变异检测预处理装置、检测装置、判定装置和系统 |
WO2020244654A1 (en) * | 2019-06-06 | 2020-12-10 | Apollomics Inc. (Hangzhou) | Method for treating cancer patients using c-met inhibitor |
CN111718982A (zh) * | 2020-07-09 | 2020-09-29 | 深圳市海普洛斯生物科技有限公司 | 一种肿瘤组织单样本体细胞突变检测方法及装置 |
Non-Patent Citations (5)
Title |
---|
HISATO KAWAKAMI等: "Targeting MET Amplification as a New Oncogenic Driver", 《CANCERS》 * |
PHILLIP N GRAY等: "TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy", 《ONCOTARGET》 * |
SHIBO WU等: "High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy", 《ANN TRANSL MED》 * |
YUBO WANG等: "Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib", 《LUNG CANCER》 * |
刘小云等: "基于分子标签二代测序技术的非小细胞肺癌驱动基因变异分析", 《分子诊断与治疗杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114512183A (zh) * | 2022-01-27 | 2022-05-17 | 北京吉因加医学检验实验室有限公司 | 一种预测met基因扩增或多倍体的方法及装置 |
CN115376609A (zh) * | 2022-10-24 | 2022-11-22 | 广州燃石医学检验所有限公司 | 一种判别met基因拷贝数扩增类型的方法及装置 |
Also Published As
Publication number | Publication date |
---|---|
CN112592976B (zh) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7458360B2 (ja) | 疾患細胞不均一性を示す疾患の検出および処置、ならびに通信試験結果のためのシステムおよび方法 | |
Ding et al. | Expanding the computational toolbox for mining cancer genomes | |
JP6829211B2 (ja) | 癌スクリーニング及び胎児分析のための変異検出 | |
KR102521842B1 (ko) | 암 검출을 위한 혈장 dna의 돌연변이 분석 | |
CN107849612B (zh) | 比对和变体测序分析管线 | |
WO2018090298A2 (en) | Systems and methods for monitoring lifelong tumor evolution | |
CN112805563A (zh) | 用于评估和/或治疗癌症的无细胞dna | |
US20210065842A1 (en) | Systems and methods for determining tumor fraction | |
CN111647648A (zh) | 一种用于检测乳腺癌基因突变的基因panel及其检测方法与应用 | |
CN115287348A (zh) | Dna混合物中组织的单倍型的甲基化模式分析 | |
KR102029393B1 (ko) | 무세포 dna를 포함하는 샘플에서 순환 종양 dna를 검출하는 방법 및 그 용도 | |
CN112592976B (zh) | 一种检测met基因扩增的方法及装置 | |
CN111785324B (zh) | 一种微卫星不稳定分析方法及装置 | |
CN113096728B (zh) | 一种微小残余病灶的检测方法、装置、存储介质及设备 | |
AU2014346680A1 (en) | Targeted screening for mutations | |
Mancini-DiNardo et al. | Detection of large rearrangements in a hereditary pan-cancer panel using next-generation sequencing | |
CN116631508B (zh) | 肿瘤特异性突变状态的检测方法及其应用 | |
CN110564851A (zh) | 一组用于非超突变型直肠癌分子分型的基因及其应用 | |
CA3099612C (en) | Method of cancer prognosis by assessing tumor variant diversity by means of establishing diversity indices | |
US20230197277A1 (en) | Assessment and Quantification of Imperfect dsDNA Break Repair for Cancer Diagnosis and Treatment | |
CN114155911A (zh) | 一种矫正肿瘤突变负荷的方法及系统 | |
Leung et al. | Analytical validation of a 37-gene next generation sequencing panel for myeloid malignancies and review of initial findings, including reclassification of Acute Myeloid Leukemias and Myelodysplastic Syndromes using the 2022 WHO/ICC/ELN guidelines | |
Zaheed et al. | Investigating the suitability of cell lines as models for the major subtypes of epithelial ovarian cancer. | |
McNulty et al. | Tumor Mutational Profiling by Next-Generation Sequencing | |
CN114350811A (zh) | 一种成人脑胶质瘤分子分型NGS panel及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Method and Device for Detecting MET Gene Amplification Effective date of registration: 20221118 Granted publication date: 20210921 Pledgee: Shenzhen hi tech investment small loan Co.,Ltd. Pledgor: HAPLOX BIOTECHNOLOGY (SHENZHEN) Co.,Ltd. Registration number: Y2022980022405 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210921 Pledgee: Shenzhen hi tech investment small loan Co.,Ltd. Pledgor: HAPLOX BIOTECHNOLOGY (SHENZHEN) Co.,Ltd. Registration number: Y2022980022405 |